These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 17555466)
1. A re-evaluation of kava (Piper methysticum). Ernst E Br J Clin Pharmacol; 2007 Oct; 64(4):415-7. PubMed ID: 17555466 [No Abstract] [Full Text] [Related]
2. Kava Hepatotoxicity: Are we any closer to the truth? Anke J; Ramzan I Planta Med; 2004 Mar; 70(3):193-6. PubMed ID: 15114493 [TBL] [Abstract][Full Text] [Related]
3. Another FDA warning: Kava supplements. Parkman CA Case Manager; 2002; 13(4):26-8. PubMed ID: 12131903 [No Abstract] [Full Text] [Related]
4. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Sarris J; LaPorte E; Schweitzer I Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405 [TBL] [Abstract][Full Text] [Related]
6. Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract. Robinson V; Bergfeld WF; Belsito DV; Klaassen CD; Marks JG; Shank RC; Slaga TJ; Snyder PW; ; Andersen FA Int J Toxicol; 2009; 28(6 Suppl):175S-88S. PubMed ID: 19966149 [TBL] [Abstract][Full Text] [Related]
7. A systematic review of the safety of kava extract in the treatment of anxiety. Stevinson C; Huntley A; Ernst E Drug Saf; 2002; 25(4):251-61. PubMed ID: 11994028 [TBL] [Abstract][Full Text] [Related]
8. [Acute hepatitis due to kava-kava and St John's Wort: an immune-mediated mechanism?]. Teschke R Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1880-1; author reply 1882-3. PubMed ID: 16915552 [No Abstract] [Full Text] [Related]
9. Risk of kava hepatotoxicity and the FDA consumer advisory. Teschke R; Schulze J JAMA; 2010 Nov; 304(19):2174-5. PubMed ID: 21081732 [No Abstract] [Full Text] [Related]
10. Synthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion. Zou L; Harkey MR; Henderson GL Planta Med; 2005 Feb; 71(2):142-6. PubMed ID: 15729622 [TBL] [Abstract][Full Text] [Related]
11. Relevant hepatotoxic effects of kava still need to be proven. A statement of the Society for Medicinal Plant Research. Society for Medicinal Plant Research Planta Med; 2003 Nov; 69(11):971-2. PubMed ID: 14735431 [No Abstract] [Full Text] [Related]
12. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Russmann S; Barguil Y; Cabalion P; Kritsanida M; Duhet D; Lauterburg BH Eur J Gastroenterol Hepatol; 2003 Sep; 15(9):1033-6. PubMed ID: 12923378 [TBL] [Abstract][Full Text] [Related]
13. [Piper methysticum (kava) under discussion: observations on quality, effectiveness and safety]. Schmidt M; Nahrstedt A; Lüpke NP Wien Med Wochenschr; 2002; 152(15-16):382-8. PubMed ID: 12244883 [TBL] [Abstract][Full Text] [Related]
14. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. Schmidt M J Altern Complement Med; 2003 Apr; 9(2):183-7; author reply 187-8. PubMed ID: 12804070 [No Abstract] [Full Text] [Related]